{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:05:50Z","timestamp":1795028750188,"version":"4.10.2"},"reference-count":289,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Over the past decades, significant progress has been made in cancer treatment, including chemotherapy, targeted therapy, and more recently, immunotherapy. However, only a limited number of patients achieve cure with these therapies. A major challenge lies in acquired resistance to cancer treatments, where patients initially respond but eventually develop resistance and relapse. The underlying mechanisms of acquired resistance are still emerging, encompassing both tumor cell-intrinsic and extrinsic factors, such as the selection of pre-existing resistant clones, acquired genetic mutations, and alterations in the tumor microenvironment. In recent years, several new concepts and significant advances have emerged in this field, such as epigenetic alterations, lineage plasticity, metabolic reprogramming, and cellular crosstalk and signaling within the tumor microenvironment. This review systematically summarizes these advances, aiming to provide a comprehensive theoretical framework that integrates emerging concepts of resistance, while also offering a translational perspective focused on identifying actionable therapeutic targets and guiding the development of next-generation combination strategies to prevent or overcome acquired resistance in the clinic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004048","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:00:15Z","timestamp":1773720015000},"page":"1272-1302","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Acquired resistance of cancer therapies: Mechanisms and perspectives"],"prefix":"10.1097","volume":"139","author":[{"given":"Manli","family":"Wang","sequence":"first","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"},{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Chen","sequence":"additional","affiliation":[{"name":"West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyue","family":"Gai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunxi","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"R1-20260505","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1097\/CM9.0000000000003703","article-title":"Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy","volume":"138","author":"Peng","year":"2025","journal-title":"Chin Med J"},{"key":"R2-20260505","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (mdx-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"R3-20260505","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20260505","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun Signal"},{"key":"R5-20260505","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","article-title":"Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer","volume":"6","author":"Gu","year":"2025","journal-title":"Mol Biomed"},{"key":"R6-20260505","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: Chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R7-20260505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179451","article-title":"Battling chemoresistance in cancer: Root causes and strategies to uproot them","volume":"22","author":"Ramos","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R8-20260505","first-page":"6","article-title":"Novel players in the development of chemoresistance in ovarian cancer: Ovarian cancer stem cells, non-coding rna and nuclear receptors","volume":"7","author":"Alam","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"R9-20260505","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.21037\/jtd-24-1078","article-title":"Resistance mechanisms of non-small cell lung cancer and improvement of treatment effects through nanotechnology: A narrative review","volume":"16","author":"Cao","year":"2024","journal-title":"J Thorac Dis"},{"key":"R10-20260505","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41419-021-03804-7","article-title":"Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer","volume":"12","author":"Long","year":"2021","journal-title":"Cell Death Dis"},{"key":"R11-20260505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212402","article-title":"Multilevel mechanisms of cancer drug resistance","volume":"25","author":"Roszkowska","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R12-20260505","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fonc.2012.00186","article-title":"Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma","volume":"2","author":"Yoshimoto","year":"2012","journal-title":"Front Oncol"},{"key":"R13-20260505","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s13071-019-3792-1","article-title":"DNA damage response and repair in perspective: Aedes aegypti, drosophila melanogaster and homo sapiens","volume":"12","author":"Mota","year":"2019","journal-title":"Parasit Vectors"},{"key":"R14-20260505","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13148-025-01961-6","article-title":"Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms","volume":"17","author":"Yu","year":"2025","journal-title":"Clin Epigenetics"},{"key":"R15-20260505","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI15475","article-title":"Inactivation of HMLH1 and HMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples","volume":"111","author":"Wang","year":"2003","journal-title":"J Clin Invest"},{"key":"R16-20260505","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.07.020","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment","volume":"175","author":"Taieb","year":"2022","journal-title":"Eur J Cancer"},{"key":"R17-20260505","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"R18-20260505","article-title":"Homologous recombination pathway alternation predicts prognosis of colorectal cancer with chemotherapy","volume":"13","author":"Lin","year":"2022","journal-title":"Front Pharmacol"},{"key":"R19-20260505","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41586-025-09078-9","article-title":"Dynamic assemblies and coordinated reactions of non-homologous end joining","volume":"643","author":"Liu","year":"2025","journal-title":"Nature"},{"key":"R20-20260505","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"R21-20260505","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ccell.2015.06.004","article-title":"DNA-pkcs-mediated transcriptional regulation drives prostate cancer progression and metastasis","volume":"28","author":"Goodwin","year":"2015","journal-title":"Cancer Cell"},{"key":"R22-20260505","doi-asserted-by":"crossref","first-page":"26356","DOI":"10.1073\/pnas.2002917117","article-title":"Rational combination therapy for hepatocellular carcinoma with parp1 and DNA-PK inhibitors","volume":"117","author":"Wang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-20260505","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/cas.12998","article-title":"Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair","volume":"107","author":"Sunada","year":"2016","journal-title":"Cancer Sci"},{"key":"R24-20260505","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1038\/s41467-025-60228-z","article-title":"Elevated nonhomologous end-joining by AATF enables efficient DNA damage repair and therapeutic resistance in glioblastoma","volume":"16","author":"Mi","year":"2025","journal-title":"Nat Commun"},{"key":"R25-20260505","first-page":"1","article-title":"Cancer multidrug resistance (MDR): A major impediment to effective chemotherapy","volume":"9","author":"Ullah","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"R26-20260505","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of atp-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R27-20260505","first-page":"4483","article-title":"Progress and challenges of multidrug resistance proteins in diseases","volume":"12","author":"Ding","year":"2022","journal-title":"Am J Cancer Res"},{"key":"R28-20260505","article-title":"Correction: Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal wilms tumour patients","volume":"8","author":"Hontecillas-Prieto","year":"2017","journal-title":"Oncotarget"},{"key":"R29-20260505","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","article-title":"Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)","volume":"22","author":"Doyle","year":"2003","journal-title":"Oncogene"},{"key":"R30-20260505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246246","article-title":"Mechanisms of drug resistance in ovarian cancer and associated gene targets","volume":"14","author":"Alatise","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R31-20260505","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: A shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R32-20260505","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ccell.2025.04.010","article-title":"Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"R33-20260505","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.1038\/s41467-025-61024-5","article-title":"EZH2 loss promotes gastric squamous cell carcinoma","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"R34-20260505","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41586-023-05838-7","article-title":"RHOJ controls emt-associated resistance to chemotherapy","volume":"616","author":"Debaugnies","year":"2023","journal-title":"Nature"},{"key":"R35-20260505","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41568-023-00581-7","article-title":"EMT in chemoresistance","volume":"23","author":"Dart","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"R36-20260505","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: Landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R37-20260505","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and brca1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R38-20260505","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4161\/epi.28601","article-title":"Integrated analysis of DNA methylation and mrna expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer","volume":"9","author":"Zhang","year":"2014","journal-title":"Epigenetics"},{"key":"R39-20260505","article-title":"The interaction between DNMT1 and high-mannose CD133 maintains the slow-cycling state and tumorigenic potential of glioma stem cell","volume":"9","author":"Wei","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"R40-20260505","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cbin.10734","article-title":"TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer","volume":"41","author":"Han","year":"2017","journal-title":"Cell Biol Int"},{"key":"R41-20260505","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R42-20260505","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41388-018-0459-x","article-title":"Mir-137 mediates the functional link between c-MYC and EZH2 that regulates cisplatin resistance in ovarian cancer","volume":"38","author":"Sun","year":"2019","journal-title":"Oncogene"},{"key":"R43-20260505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101585","article-title":"The histone demethylase LSD1\/Kappadm1a mediates chemoresistance in breast cancer via regulation of a stem cell program","volume":"11","author":"Verigos","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R44-20260505","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e75","article-title":"Sp1-induced lncrna MCF2l-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1\/IGF2\/MEK\/ERK axis","volume":"33","author":"Zhu","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"R45-20260505","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26030936","article-title":"Role of hypoxia-associated long noncoding RNAS in cancer chemo-therapy resistance","volume":"26","author":"Elahi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R46-20260505","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41576-018-0073-3","article-title":"Piwi-interacting RNAs: Small RNAs with big functions","volume":"20","author":"Ozata","year":"2019","journal-title":"Nat Rev Genet"},{"key":"R47-20260505","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1038\/s41467-025-60424-x","article-title":"CRISPR screen decodes SWI\/SNF chromatin remodeling complex assembly","volume":"16","author":"Schwaemmle","year":"2025","journal-title":"Nat Commun"},{"key":"R48-20260505","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2217\/epi-2017-0034","article-title":"The BRG1 atpase of human SWI\/SNF chromatin remodeling enzymes as a driver of cancer","volume":"9","author":"Wu","year":"2017","journal-title":"Epigenomics"},{"key":"R49-20260505","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","article-title":"Tumor cell metabolism: Cancer\u2019s achilles\u2019 heel","volume":"13","author":"Kroemer","year":"2008","journal-title":"Cancer Cell"},{"key":"R50-20260505","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41420-025-02554-1","article-title":"The role and mechanism of fatty acid oxidation in cancer drug resistance","volume":"11","author":"Lei","year":"2025","journal-title":"Cell Death Discov"},{"key":"R51-20260505","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-022-00358-1","article-title":"Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer","volume":"3","author":"Guo","year":"2022","journal-title":"Nat Cancer"},{"key":"R52-20260505","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R53-20260505","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-021-01463-y","article-title":"Cancer associated-fibroblast-derived exosomes in cancer progression","volume":"20","author":"Li","year":"2021","journal-title":"Mol Cancer"},{"key":"R54-20260505","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12967-025-06643-8","article-title":"Unraveling the role of M2 TAMs in ovarian cancer dynamics: A systematic review","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"R55-20260505","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R56-20260505","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12935-019-0771-8","article-title":"Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma","volume":"19","author":"Fu","year":"2019","journal-title":"Cancer Cell Int"},{"key":"R57-20260505","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"R58-20260505","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"R59-20260505","article-title":"Hypoxia-inducible factor-dependent and independent mechanisms underlying chemoresistance of hypoxic cancer cells","volume":"16","author":"Lee","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R60-20260505","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-025-01684-4","article-title":"Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance","volume":"18","author":"Shang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"R61-20260505","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: New insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell Death Dis"},{"key":"R62-20260505","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0031-6997(24)01448-0","article-title":"Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation","volume":"52","author":"Griffioen","year":"2000","journal-title":"Pharmacol Rev"},{"key":"R63-20260505","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"R64-20260505","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"R65-20260505","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"R66-20260505","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/2159-8290.CD-20-1571","article-title":"Loss of optineurin drives cancer immune evasion via palmitoylation-dependent ifngr1 lysosomal sorting and degradation","volume":"11","author":"Du","year":"2021","journal-title":"Cancer Discov"},{"key":"R67-20260505","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"R68-20260505","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"R69-20260505","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"R70-20260505","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"R71-20260505","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ccell.2025.01.009","article-title":"Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma","volume":"43","author":"Schiantarelli","year":"2025","journal-title":"Cancer Cell"},{"key":"R72-20260505","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J Clin Oncol"},{"key":"R73-20260505","article-title":"Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high","volume":"3","author":"Middha","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"R74-20260505","article-title":"Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer","volume":"122","author":"Wang","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R75-20260505","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ccell.2022.06.011","article-title":"Oncogenic collagen i homotrimers from cancer cells bind to alpha3beta1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer","volume":"40","author":"Chen","year":"2022","journal-title":"Cancer Cell"},{"key":"R76-20260505","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"R77-20260505","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s40425-019-0780-0","article-title":"Secondary resistance to immunotherapy associated with beta-catenin pathway activation or pten loss in metastatic melanoma","volume":"7","author":"Trujillo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R78-20260505","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing BATF3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"R79-20260505","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/2159-8290.CD-19-1416","article-title":"Inactivation of FBXW7 impairs dsrna sensing and confers resistance to PD-1 blockade","volume":"10","author":"Gstalder","year":"2020","journal-title":"Cancer Discov"},{"key":"R80-20260505","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"R81-20260505","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41419-023-05878-x","article-title":"Epigenetically modified AP-2alpha by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression","volume":"14","author":"Long","year":"2023","journal-title":"Cell Death Dis"},{"key":"R82-20260505","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cellimm.2018.12.010","article-title":"Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma","volume":"336","author":"Hong","year":"2019","journal-title":"Cell Immunol"},{"key":"R83-20260505","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11060-024-04689-0","article-title":"Suberanilohydroxamic acid (saha), a HDAC inhibitor, suppresses the effect of treg cells by targeting the c-MYC\/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy","volume":"168","author":"Sun","year":"2024","journal-title":"J Neurooncol"},{"key":"R84-20260505","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1038\/s41418-023-01217-x","article-title":"METTL3 inhibition induced by M2 macrophage-derived extracellular vesicles drives anti-PD-1 therapy resistance via m6a-cd70-mediated immune suppression in thyroid cancer","volume":"30","author":"Ning","year":"2023","journal-title":"Cell Death Differ"},{"key":"R85-20260505","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"R86-20260505","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R87-20260505","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"R88-20260505","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"R89-20260505","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate t-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"R90-20260505","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"R91-20260505","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nm.4086","article-title":"Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers","volume":"22","author":"Saito","year":"2016","journal-title":"Nat Med"},{"key":"R92-20260505","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"R93-20260505","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R94-20260505","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"key":"R95-20260505","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from fap-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"R96-20260505","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","article-title":"Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer","volume":"57","author":"Yan","year":"2025","journal-title":"Nat Genet"},{"key":"R97-20260505","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res"},{"key":"R98-20260505","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R99-20260505","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: Tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"key":"R100-20260505","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat Med"},{"key":"R101-20260505","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium fasl establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med"},{"key":"R102-20260505","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004561","article-title":"Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-i and apm deficiencies","volume":"10","author":"Minnar","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R103-20260505","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-020-01786-6","article-title":"Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion","volume":"40","author":"Fang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"R104-20260505","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1158\/0008-5472.CAN-17-3876","article-title":"Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer","volume":"78","author":"Quaranta","year":"2018","journal-title":"Cancer Res"},{"key":"R105-20260505","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00262-013-1508-5","article-title":"Frequencies of circulating mdsc correlate with clinical outcome of melanoma patients treated with ipilimumab","volume":"63","author":"Meyer","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"R106-20260505","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","article-title":"Myeloid-derived suppressor cells suppress antitumor immune responses through ido expression and correlate with lymph node metastasis in patients with breast cancer","volume":"190","author":"Yu","year":"2013","journal-title":"J Immunol"},{"key":"R107-20260505","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.23054","article-title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKP30 receptor","volume":"50","author":"Hoechst","year":"2009","journal-title":"Hepatology"},{"key":"R108-20260505","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines -gamma and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"R109-20260505","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"R110-20260505","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","article-title":"Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol Cancer"},{"key":"R111-20260505","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ni.3838","article-title":"Srebp-controlled glucose metabolism is essential for NK cell functional responses","volume":"18","author":"Assmann","year":"2017","journal-title":"Nat Immunol"},{"key":"R112-20260505","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","article-title":"Navigating metabolic pathways to enhance antitumour immunity and immunotherapy","volume":"16","author":"Li","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R113-20260505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: The constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"R114-20260505","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/CM9.0000000000003149","article-title":"Cancer therapy-related interstitial lung disease","volume":"138","author":"Zhou","year":"2025","journal-title":"Chin Med J"},{"key":"R115-20260505","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of nsclc with uncommon, non exon 20 insertions, EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R116-20260505","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"R117-20260505","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of nsclc post-osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R118-20260505","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"Azd9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"R119-20260505","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with egfr T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol"},{"key":"R120-20260505","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R121-20260505","article-title":"Afatinib as a potential therapeutic option for patients with nsclc with EGFR G724S","volume":"2","author":"Wei","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"R122-20260505","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.lungcan.2017.04.003","article-title":"Emergence of novel and dominant acquired EGFR solvent-front mutations at gly796 (G796S\/R) together with c797s\/r and l792f\/h mutations in one EGFR (l858R\/T790M) nsclc patient who progressed on osimertinib","volume":"108","author":"Ou","year":"2017","journal-title":"Lung Cancer"},{"key":"R123-20260505","doi-asserted-by":"crossref","first-page":"49671","DOI":"10.18632\/oncotarget.17913","article-title":"EGFR G796D mutation mediates resistance to osimertinib","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"R124-20260505","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101266","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"82","author":"Du","year":"2025","journal-title":"Drug Resist Updat"},{"key":"R125-20260505","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R126-20260505","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jtho.2019.07.027","article-title":"Capmatinib and osimertinib\u00a0combination therapy for EGFR-mutant lung adenocarcinoma","volume":"15","author":"Gautschi","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R127-20260505","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.cllc.2021.06.002","article-title":"A case report of successful treatment with crizotinib to overcome resistance to osimertinib in an egfr mutated non-small-cell lung cancer patient harboring an acquired MET exon 14 mutation","volume":"23","author":"Pinquie","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"R128-20260505","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the raf\/mek\/erk pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"R129-20260505","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R130-20260505","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1158\/1078-0432.CCR-15-1915","article-title":"Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors","volume":"22","author":"Ortiz-Cuaran","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R131-20260505","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Transl Med"},{"key":"R132-20260505","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with egfr-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R133-20260505","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a\u00a0subset of EGFR-mutant lung cancers at risk for\u00a0histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R134-20260505","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J Clin Oncol"},{"key":"R135-20260505","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41388-024-03244-5","article-title":"TFF3 drives hippo dependent EGFR-TKI resistance in lung adenocarcinoma","volume":"44","author":"Zhang","year":"2025","journal-title":"Oncogene"},{"key":"R136-20260505","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-025-02285-y","article-title":"Nnmt promotes acquired EGFR-TKI resistance by forming egr1 and lactate-mediated double positive feedback loops in non-small cell lung cancer","volume":"24","author":"Dai","year":"2025","journal-title":"Mol Cancer"},{"key":"R137-20260505","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/CM9.0000000000003405","article-title":"Role of silent mutations in KRAS -mutant tumors","volume":"138","author":"Lu","year":"2025","journal-title":"Chin Med J"},{"key":"R138-20260505","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"R139-20260505","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","article-title":"Kras secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: Insights from in\u00a0vitro experiments","volume":"16","author":"Koga","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R140-20260505","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"R141-20260505","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in ras-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R142-20260505","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"key":"R143-20260505","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm1208-1315","article-title":"Targeting RAS and PI3K in lung cancer","volume":"14","author":"Downward","year":"2008","journal-title":"Nat Med"},{"key":"R144-20260505","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1513\/pats.200809-107LC","article-title":"KRAS mutations in non-small cell lung cancer","volume":"6","author":"Riely","year":"2009","journal-title":"Proc Am Thorac Soc"},{"key":"R145-20260505","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with braf and mek inhibitors for melanoma: Latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"R146-20260505","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to kras G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R147-20260505","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","article-title":"Mechanisms of resistance to KRAS(G12C)-targeted therapy","volume":"11","author":"Akhave","year":"2021","journal-title":"Cancer Discov"},{"key":"R148-20260505","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ccell.2021.02.009","article-title":"A gene expression signature associated with \u201cK-RAS addiction\u201d reveals regulators of emt and tumor cell survival","volume":"39","author":"Singh","year":"2021","journal-title":"Cancer Cell"},{"key":"R149-20260505","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","article-title":"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3","volume":"7","author":"Sun","year":"2014","journal-title":"Cell Rep"},{"key":"R150-20260505","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R151-20260505","first-page":"355","article-title":"Evolving standards of care and new challenges in the management of HER2-positive breast cancer","volume":"70","author":"Choong","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R152-20260505","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NASBP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J Clin Oncol"},{"key":"R153-20260505","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (cleopatra): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"R154-20260505","doi-asserted-by":"crossref","first-page":"113494","DOI":"10.18632\/oncotarget.23054","article-title":"PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"R155-20260505","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/JCO.2018.36.15_suppl.4038","article-title":"Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab","volume":"36","author":"Kashiwada","journal-title":"Journal of Clinical Oncology"},{"key":"R156-20260505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102418","article-title":"Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review","volume":"108","author":"Blang\u00e9","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R157-20260505","doi-asserted-by":"crossref","first-page":"71790","DOI":"10.18632\/oncotarget.12374","article-title":"Jwa down-regulates HER2 expression via C-CBl and induces lapatinib resistance in human gastric cancer cells","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"R158-20260505","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1372571","article-title":"Bioinformatics analysis of potential key genes in trastuzumab-resistant gastric cancer","volume":"2019","author":"Yang","year":"2019","journal-title":"Dis Markers"},{"key":"R159-20260505","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/gutjnl-2018-316522","article-title":"Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer","volume":"68","author":"Wang","year":"2019","journal-title":"Gut"},{"key":"R160-20260505","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.254","article-title":"Clinical implications of plasma ctdna features and dynamics in gastric cancer treated with HER2-targeted therapies","volume":"10","author":"Zhang","year":"2020","journal-title":"Clin Transl Med"},{"key":"R161-20260505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041130","article-title":"Resistance to antibody-drug conjugates targeting HER2 in breast cancer: Molecular landscape and future challenges","volume":"15","author":"Guidi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R162-20260505","first-page":"5123","article-title":"Nh2-terminally truncated HER-2\/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer","volume":"58","author":"Christianson","year":"1998","journal-title":"Cancer Res"},{"key":"R163-20260505","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1535-7163.MCT-10-0991","article-title":"Truncated ERBB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ERBB2 kinase inhibitors","volume":"10","author":"Xia","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"R164-20260505","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/AKT signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"R165-20260505","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 low, ULTRA-low, and novel complementary biomarkers: Expanding the spectrum of HER2 positivity in breast cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front Mol Biosci"},{"key":"R166-20260505","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1038\/s41388-021-01801-w","article-title":"ST6GAL1 targets the ectodomain of ERBB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab","volume":"40","author":"Duarte","year":"2021","journal-title":"Oncogene"},{"key":"R167-20260505","first-page":"2997","article-title":"Increasing HER2 \u03b12,6 sialylation facilitates gastric cancer progression and resistance via the akt and erk pathways","volume":"40","author":"Liu","year":"2018","journal-title":"Oncol Rep"},{"key":"R168-20260505","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104624","article-title":"Challenges and prospects in HER2-positive breast cancer-targeted therapy","volume":"207","author":"Li","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"R169-20260505","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/1535-7163.MCT-11-0754","article-title":"Met activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells","volume":"11","author":"Chen","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"R170-20260505","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/cas.12290","article-title":"Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells","volume":"104","author":"Sato","year":"2013","journal-title":"Cancer Sci"},{"key":"R171-20260505","doi-asserted-by":"crossref","first-page":"10243","DOI":"10.18632\/oncotarget.7200","article-title":"ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3","volume":"7","author":"Ebbing","year":"2016","journal-title":"Oncotarget"},{"key":"R172-20260505","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"R173-20260505","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-15-2499","article-title":"Relationship between tumor biomarkers and efficacy in emilia, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer","volume":"22","author":"Baselga","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R174-20260505","doi-asserted-by":"crossref","DOI":"10.1038\/srep11634","article-title":"Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance","volume":"5","author":"Zuo","year":"2015","journal-title":"Sci Rep"},{"key":"R175-20260505","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: From function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"R176-20260505","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation alk inhibitors in alk-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"R177-20260505","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","article-title":"ALK mutations confer differential oncogenic activation and sensitivity to alk inhibition therapy in neuroblastoma","volume":"26","author":"Bresler","year":"2014","journal-title":"Cancer Cell"},{"key":"R178-20260505","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002950","article-title":"Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma","volume":"3","author":"Bresler","year":"2011","journal-title":"Sci Transl Med"},{"key":"R179-20260505","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation l1198f","volume":"374","author":"Shaw","year":"2016","journal-title":"N Engl J Med"},{"key":"R180-20260505","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","article-title":"Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer","volume":"3","author":"Shiba-Ishii","year":"2022","journal-title":"Nat Cancer"},{"key":"R181-20260505","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"key":"R182-20260505","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J Clin Oncol"},{"key":"R183-20260505","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-023-38195-0","article-title":"Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed\/refractory ALK-driven neuroblastoma","volume":"14","author":"Berko","year":"2023","journal-title":"Nat Commun"},{"key":"R184-20260505","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41598-017-00219-3","article-title":"Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors","volume":"7","author":"Ohshima","year":"2017","journal-title":"Sci Rep"},{"key":"R185-20260505","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","article-title":"MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer","volume":"26","author":"Dagogo-Jack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R186-20260505","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R187-20260505","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/1078-0432.CCR-12-0392","article-title":"Activation of her family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer","volume":"18","author":"Tanizaki","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R188-20260505","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nm.3667","article-title":"Rationale for co-targeting IGF-1R and alk in alk fusion-positive lung cancer","volume":"20","author":"Lovly","year":"2014","journal-title":"Nat Med"},{"key":"R189-20260505","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1158\/2767-9764.CRC-24-0338","article-title":"Long-lasting response to lorlatinib in patients with alk-driven relapsed or refractory neuroblastoma monitored with circulating tumor DNA analysis","volume":"4","author":"Ek","year":"2024","journal-title":"Cancer Res Commun"},{"key":"R190-20260505","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1038\/sj.onc.1207703","article-title":"Selective inhibition of STAT3 induces apoptosis and g(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma","volume":"23","author":"Amin","year":"2004","journal-title":"Oncogene"},{"key":"R191-20260505","first-page":"1657","article-title":"IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma","volume":"136","author":"Prokoph","year":"2020","journal-title":"Blood"},{"key":"R192-20260505","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"R193-20260505","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910581","article-title":"Targeting yap to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer","volume":"11","author":"Yun","year":"2019","journal-title":"EMBO Mol Med"},{"key":"R194-20260505","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"R195-20260505","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother Oncol"},{"key":"R196-20260505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215328","article-title":"PARP inhibitors and haematological malignancies-friend or foe?","volume":"13","author":"Skelding","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R197-20260505","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13073-025-01488-8","article-title":"DNA repair and the contribution to chemotherapy resistance","volume":"17","author":"Nesic","year":"2025","journal-title":"Genome Med"},{"key":"R198-20260505","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12935-022-02664-1","article-title":"Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment","volume":"22","author":"Xu","year":"2022","journal-title":"Cancer Cell Int"},{"key":"R199-20260505","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s40265-025-02200-1","article-title":"Senaparib: First approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"R200-20260505","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"R201-20260505","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"R202-20260505","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115883","article-title":"Novel microtubule inhibitor sq overcomes multidrug resistance in MCF-7\/ADR cells by inhibiting BCRP function and mediating apoptosis","volume":"436","author":"Chang","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"R203-20260505","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21739","article-title":"Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting p-glycoprotein (p-gp)","volume":"41","author":"Zhang","year":"2021","journal-title":"Med Res Rev"},{"key":"R204-20260505","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ejmech.2017.01.019","article-title":"N-alkanol-n-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy","volume":"127","author":"Teodori","year":"2017","journal-title":"Eur J Med Chem"},{"key":"R205-20260505","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1021\/acs.jmedchem.0c00337","article-title":"Discovery of potent inhibitors against p-glycoprotein-mediated multidrug resistance aided by late-stage functionalization of a 2-(4-(pyridin-2-yl)phenoxy)pyridine analogue","volume":"63","author":"Ma","year":"2020","journal-title":"J Med Chem"},{"key":"R206-20260505","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1021\/acs.jmedchem.8b01655","article-title":"Design, biological evaluation, and molecular modeling of tetrahydroisoquinoline derivatives: Discovery of a potent p-glycoprotein ligand overcoming multidrug resistance in cancer stem cells","volume":"62","author":"Riganti","year":"2019","journal-title":"J Med Chem"},{"key":"R207-20260505","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113848","article-title":"Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2\/ABCB1 inhibitor","volume":"175","author":"Cai","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"R208-20260505","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s12276-024-01326-8","article-title":"SMYD family in cancer: Epigenetic regulation and molecular mechanisms of cancer proliferation, metastasis, and drug resistance","volume":"56","author":"Han","year":"2024","journal-title":"Exp Mol Med"},{"key":"R209-20260505","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"R210-20260505","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108640","article-title":"Therapeutic targeting of DNA methylation alterations in cancer","volume":"258","author":"Lee","year":"2024","journal-title":"Pharmacol Ther"},{"key":"R211-20260505","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13148-021-01154-x","article-title":"DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: Mechanism and clinical application","volume":"13","author":"Hu","year":"2021","journal-title":"Clin Epigenetics"},{"key":"R212-20260505","first-page":"291","article-title":"A case of relapsed\/refractory CD56-positive acute promyelocytic leukemia, in which complete molecular remission was achieved following combination therapy with venetoclax and azacitidine","volume":"51","author":"Sekiguchi","year":"2024","journal-title":"Gan To Kagaku Ryoho"},{"key":"R213-20260505","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R214-20260505","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"R215-20260505","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102903","article-title":"Efficacy of hdac inhibitors belinostat and panobinostat against cisplatin-sensitive and cisplatin-resistant testicular germ cell tumors","volume":"12","author":"Lobo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R216-20260505","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbrc.2022.03.070","article-title":"Improvement of resistance to oxaliplatin by vorinostat in human colorectal cancer cells through inhibition of NRF2 nuclear translocation","volume":"607","author":"Tanaka","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"R217-20260505","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: A shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R218-20260505","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.ccell.2022.08.010","article-title":"Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"R219-20260505","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1097\/JS9.0000000000002611","article-title":"Prostate cancer stem cell dynamics in the evolution of drug resistance","volume":"111","author":"Zhang","year":"2025","journal-title":"Int J Surg"},{"key":"R220-20260505","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat Commun"},{"key":"R221-20260505","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70458","article-title":"Persistent lineage plasticity driving lung cancer development and progression","volume":"15","author":"Meng","year":"2025","journal-title":"Clin Transl Med"},{"key":"R222-20260505","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40170-016-0156-6","article-title":"Metabolic requirements for cancer cell proliferation","volume":"4","author":"Keibler","year":"2016","journal-title":"Cancer Metab"},{"key":"R223-20260505","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"key":"R224-20260505","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nature22359","article-title":"Cps1 maintains pyrimidine pools and DNA synthesis in kras\/lkb1-mutant lung cancer cells","volume":"546","author":"Kim","year":"2017","journal-title":"Nature"},{"key":"R225-20260505","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2013.09.041","article-title":"Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer","volume":"155","author":"Kim","year":"2013","journal-title":"Cell"},{"key":"R226-20260505","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: Contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw"},{"key":"R227-20260505","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: Updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Cancer"},{"key":"R228-20260505","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R229-20260505","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: A pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"key":"R230-20260505","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"R231-20260505","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","article-title":"Entinostat plus pembrolizumab in patients with metastatic nsclc previously treated with anti-PD-(L)1 therapy","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R232-20260505","article-title":"Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"key":"R233-20260505","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"R234-20260505","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R235-20260505","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of t cell responses: Mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"R236-20260505","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1546717","article-title":"Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors","volume":"16","author":"Alsaafeen","year":"2025","journal-title":"Front Immunol"},{"key":"R237-20260505","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted cd8(+) T\u00a0cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"R238-20260505","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-23-2701","article-title":"Atg-101 is a tetravalent PD-L1\u00d74-1BB bispecific antibody that stimulates antitumor immunity through PD-L1 blockade and PD-L1-directed 4-1BB activation","volume":"84","author":"Yuwen","year":"2024","journal-title":"Cancer Res"},{"key":"R239-20260505","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R240-20260505","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med Res Rev"},{"key":"R241-20260505","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1042\/BST20191055","article-title":"Targeted therapy and drug resistance in triple-negative breast cancer: The egfr axis","volume":"48","author":"Lev","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"R242-20260505","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R243-20260505","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"R244-20260505","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"R245-20260505","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of blu-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J Med Chem"},{"key":"R246-20260505","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1200\/JCO.2023.41.16_suppl.9011","article-title":"Blu-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR -mutant (EGFRM) nsclc in the phase 1\/2 symphony study","volume":"41","author":"Elamin","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"R247-20260505","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1021\/acsmedchemlett.2c00514","article-title":"Addressing the osimertinib resistance mutation EGFR-l858R\/C797S with reversible aminopyrimidines","volume":"14","author":"Grabe","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"R248-20260505","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.728155","article-title":"A phase I trial of dasatinib and osimertinib in TKI na\u00efve patients with advanced EGFR-mutant non-small-cell lung cancer","volume":"11","author":"Kim","year":"2021","journal-title":"Front Oncol"},{"key":"R249-20260505","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-4329","article-title":"Osimertinib plus selumetinib in EGFR-mutated non-small cell lung cancer after progression on eEGFR-TKIs: A phase Ib, open-label, multicenter trial (tatton part b)","author":"Yang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R250-20260505","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1158\/1078-0432.CCR-20-4084","article-title":"Phase Ib study of osimertinib in combination with navitoclax in egfr-mutant nsclc following resistance to initial EGFR therapy (etctn 9903)","volume":"27","author":"Bertino","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R251-20260505","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240435","article-title":"Inhibition of htert\/telomerase\/telomere mediates therapeutic efficacy of osimertinib in egfr mutant lung cancer","volume":"221","author":"Chen","year":"2024","journal-title":"J Exp Med"},{"key":"R252-20260505","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41420-024-02251-5","article-title":"TFAP2A drives non-small cell lung cancer (nsclc) progression and resistance to targeted therapy by facilitating the ESR2-mediated mapk pathway","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"key":"R253-20260505","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-472792","article-title":"Bispecific antibodies in non-small cell lung cancer: From targeted innovation to real-world integration","volume":"45","author":"Carlisle","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R254-20260505","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an egfr-met bispecific antibody, in diverse models of egfr exon 20 insertion-driven nsclc","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"R255-20260505","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an FC enhanced egfr\/cmet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"R257-20260505","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-024-02073-w","article-title":"Ivonescimab: First approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"R258-20260505","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"Ak112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): An open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R259-20260505","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: Recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J Clin Oncol"},{"key":"R260-20260505","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci Transl Med"},{"key":"R261-20260505","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201A, a novel HER2-targeting adc with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R262-20260505","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"R263-20260505","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1158\/1078-0432.CCR-14-2791","article-title":"Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: A paradigm for precision cancer medicine","volume":"21","author":"Katayama","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R264-20260505","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/tlcr-22-708","article-title":"Strategies to overcome resistance to alk inhibitors in non-small cell lung cancer: A narrative review","volume":"12","author":"Desai","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"R265-20260505","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-21-0221","article-title":"TPX-0131, a potent cns-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations","volume":"20","author":"Murray","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"R267-20260505","article-title":"Efficacy and tolerability of ALK\/MET combinations in patients with ALK-rearranged lung cancer with acquired MET amplification: A retrospective analysis","volume":"4","author":"Dagogo-Jack","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"R268-20260505","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-19-1104","article-title":"Diverse resistance mechanisms to the third-generation alk inhibitor lorlatinib in alk-rearranged lung cancer","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R269-20260505","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J Exp Med"},{"key":"R270-20260505","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of SHP2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J Cell Mol Med"},{"key":"R271-20260505","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R272-20260505","article-title":"Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting MTORC1\/2 complexes in pancreatic cancer","volume":"1","author":"Brown","year":"2020","journal-title":"Cell Rep Med"},{"key":"R273-20260505","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"R274-20260505","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"R275-20260505","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","article-title":"The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy","volume":"20","author":"Briere","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"R281-20260505","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: A phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat Med"},{"key":"R282-20260505","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: Biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"R283-20260505","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies-a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R284-20260505","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (mountaineer): A multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"R285-20260505","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer-an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"R286-20260505","doi-asserted-by":"crossref","first-page":"63901","DOI":"10.18632\/oncotarget.19194","article-title":"EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release","volume":"8","author":"Suh","year":"2017","journal-title":"Oncotarget"},{"key":"R287-20260505","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.951137","article-title":"Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy","volume":"13","author":"Yuan","year":"2022","journal-title":"Front Immunol"},{"key":"R289-20260505","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.chembiol.2021.02.013","article-title":"Her2-targeted antibody-drug conjugate induces host immunity against cancer stem cells","volume":"28","author":"Xia","year":"2021","journal-title":"Cell Chem Biol"},{"key":"R290-20260505","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"Ds-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase i inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J Cancer"},{"key":"R291-20260505","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (destiny-gastric02): Primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"key":"R292-20260505","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2022.05.021","article-title":"Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2\/NEU","volume":"166","author":"Yadav","year":"2022","journal-title":"Gynecol Oncol"},{"key":"R293-20260505","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with fgfr2b-selected gastric or gastro-oesophageal junction adenocarcinoma (fight): A randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"R294-20260505","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40612-9","article-title":"P70s6k\/akt dual inhibitor diacc3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab","volume":"13","author":"Fukuoka","year":"2023","journal-title":"Sci Rep"},{"key":"R295-20260505","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"R296-20260505","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/cas.16199","article-title":"Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated nsclc with high thrombospondin-1 expression","volume":"115","author":"Onda","year":"2024","journal-title":"Cancer Sci"},{"key":"R297-20260505","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.stem.2018.11.019","article-title":"Cellular plasticity in intestinal homeostasis and disease","volume":"24","author":"De Sousa","year":"2019","journal-title":"Cell Stem Cell"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:01:25Z","timestamp":1777953685000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":289,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004048","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"2025-12-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}